TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19363974
Drug: Adper Prompt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adper Prompt L-Pop (ADP)
Study: 14688150
Drug: Estrogen‐progestin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen‐progestin treatment (HRT)
Study: 11451717
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g highly concentrated n‐3 fatty acids
Study: 9540761
Drug: Meropenem (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meropenem (1 g every 8 h)
Study: 9540761
Drug: Ceftazidime (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime (2 g every 8 h) and Amikacin (15 mg/kg/day)
Study: 29406463
Drug: Lopinavir‐based antiretroviral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir‐based antiretroviral therapy (ART)
Study: 27422740
Drug: Vedolizumab (0.2,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vedolizumab (0.2, 0.5, 2.0, 6.0, or 10.0 mg/kg)
Study: 23689561
Drug: Calcium co-ingestion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium co-ingestion (15 mg/kg body mass)
Study: 23689561
Drug: Control meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control meal (3 mg/kg body mass)
Study: 22275153
Drug: No rectal
Approvals — FDA: no, EMA: no, PMDA: no
Description: No rectal distension (control)
Study: 20487528
Drug: Intensive educational
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive educational intervention consisting of group sessions with standardised information about OAC therapy, lifestyle interactions, and INR monitoring.
Study: 18779274
Drug: Milk intervention
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk intervention (3 servings/day, approximately 200 g per serving)
Study: 6372925
Drug: Treatment-as-usual (including
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-as-usual (including antidepressant medication)
Study: 24576532
Drug: paliperidone extended-release
Normalized name: Paliperidone Extended-Release Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: paliperidone extended-release (3-12 mg)
Study: 24576532
Drug: paliperidone extended-release
Normalized name: Paliperidone Extended-Release Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: paliperidone extended-release
Study: 20357160
Drug: Sugammadex (2,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugammadex (2, 4, and 16 mg/kg)
Study: 7774513
Drug: Enoxaparin 30
Normalized name: ENOXAPARIN 30MG/0.3ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 30 mg twice daily, initiated post-operatively
Study: 7774513
Drug: Enoxaparin 40
Normalized name: ENOXAPARIN 40MG/0.4ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 40 mg once daily starting preoperatively
Study: 2200994
Drug: Cefaclor (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefaclor (40 to 50 mg/kg/day for 10 days) in 3 divided doses (group 1)
Study: 2200994
Drug: Cefatrizine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefatrizine (40 to 50 mg/kg/day for 10 days) in 3 divided doses (group 2)
Study: 2200994
Drug: Cefatrizine (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefatrizine (40 to 50 mg/kg/day for 10 days) in 2 divided doses (group 3)
Study: 17389151
Drug: Telmisartan and
Normalized name: telmisartan and diuretics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan and hydrochlorothiazide combination therapy, dosage and duration not specified.
Study: 11208684
Drug: Adjusted for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjusted for baseline and treatment differences
Study: 6299620
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg of the met-enkephalin analogue, DAMME
Study: 6299620
Drug: 16 mg
Normalized name: escin 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 mg of the opiate antagonist, naloxone
Study: 6299620
Drug: Insulin-induced hypoglycaemia
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin-induced hypoglycaemia (0.15 u/kg) or naloxone (25 mg)
Study: 17405568
Drug: Resynchronization therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resynchronization therapy
Study: 15618785
Drug: Esmolol bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esmolol bolus of 1 mg/kg followed by a continuous infusion of 150 microg.kg.min
Study: 12477060
Drug: Tazarotene gel
Normalized name: Tazarotene
DrugBank: Tazarotene (DB00799)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tazarotene gel 0.1% b.i.d. for eight consecutive weeks
Study: 9174183
Drug: Liposomal amphotericin
Normalized name: Liposomal amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liposomal amphotericin B (AmBisome) at a dose of 2.8 to 3.0 mg/kg
Study: 9174183
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B deoxycholate at a standard dose of 1.0 mg/kg
Study: 3096782
Drug: Metoclopramide (MTC)
DrugBank: Metoclopramide (DB01233)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metoclopramide (MTC) administered orally in daily doses from 20 to 7.5 mg for 10 weeks
Study: 12455427
Drug: 6-session cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-session cognitive-behavioral therapy (CBT) in conjunction with usual TMD treatment
Study: 12455427
Drug: Usual conservative
Normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual conservative treatment by TMD specialist dentists
Study: 10501817
Drug: Iloprost infusion
Normalized name: Iloprost
DrugBank: Iloprost (DB01088)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iloprost infusion (3 ng kg(‐1) min(‐1) for 5 h) for 1 day (short-term treatment)
Study: 10501817
Drug: Iloprost infusion
Normalized name: Iloprost
DrugBank: Iloprost (DB01088)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iloprost infusion (3 ng kg(‐1) min(‐1) for 5 h) over a period of 28 days (long-term treatment)
Study: 10501817
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion (for 5 h) for 1 day (control treatment)
Study: 10501817
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion over a period of 28 days (placebo treatment)
Study: 8931888
Drug: New sustained
Approvals — FDA: no, EMA: no, PMDA: no
Description: New sustained release formulation of diltiazem (120 mg)
Study: 8931888
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of diltiazem (120 mg)
Study: 30333359
Drug: Oral tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tranexamic acid 250 mg twice a day
Study: 30333359
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid microinjections (4 mg/ml) monthly
Study: 21344797
Drug: Cissus quadrangularis
Normalized name: Cissus quadrangularis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cissus quadrangularis L. (3 x 2 p.c. for 4 days and then 2 x 2 p.c. for 3 days)
Study: 12147790
Drug: Angiotensin-converting enzyme
Normalized name: ACE - Angiotensin-converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor antagonists (ARB)
Study: 12147790
Drug: Antihypertensive medication
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive medication (AHM) increase
Study: 9504938
Drug: Bosentan 500
Normalized name: Bosentan
DrugBank: Bosentan (DB00559)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bosentan 500 mg once daily
Study: 9504938
Drug: Bosentan 1000
Normalized name: Bosentan
DrugBank: Bosentan (DB00559)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bosentan 1000 mg twice daily
Study: 1152314
Drug: Puppet therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Puppet therapy (puppet show designed to familiarize patients with hospital routines and procedures)
Study: 28371025
Drug: Sildenafil (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (50 mg, taken 1 hour before sexual activity, adjustable to 100 or 25 mg)
Study: 1685841
Drug: Hydrocolloid dressing
Normalized name: hydrocolloid dressing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocolloid dressing (Actiderm) plus triamcinolone acetonide (TAA) 0.1% cream applied every third day
Study: 1685841
Drug: Clobetasol propionate
Normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Clobetasol propionate 0.05% cream applied twice daily for 4 weeks
Study: 24731567
Drug: Intensive-dose atorvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive-dose atorvastatin therapy (IAT, 40mg/day)
Study: 24731567
Drug: Standard-dose atorvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose atorvastatin therapy (SAT, 20mg/day)
Study: 24731567
Drug: Low-dose atorvastatin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose atorvastatin therapy (LAT, 10mg/day)
Study: 24731567
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment groups (IAT, SAT, LAT)
Study: 19936872
Drug: SRP, chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRP, chlorhexidine gel 0.5%, three sessions of KTP laser irradiation
Study: 19936872
Drug: SRP, chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: SRP, chlorhexidine gel 0.5%
Study: 12601104
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg sumatriptan nasal spray
Study: 10229408
Drug: Immediate release
Normalized name: Namenda, immediate release oral kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate release oxycodone-APAP
Study: 8740103
Drug: Foscarnet 90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foscarnet 90 mg/kg b.i.d. 5 days for 3 weeks
Study: 8740103
Drug: Foscarnet 90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foscarnet 90 mg/kg b.i.d. daily (7 days a week)
Study: 1928165
Drug: Heparin-bonded PA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-bonded PA catheters made of polyvinylchloride or polyurethane
Study: 1928165
Drug: Heparin-bonded PA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-bonded PA catheters
Study: 6351455
Drug: Norfenefrin infusion
Normalized name: norfenefrine
DrugBank: Norfenefrine (DB13378)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norfenefrin infusion (2-4 mg/kg per minute)
Study: 26861783
Drug: Empagliflozin administration
Normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Empagliflozin administration
Study: 26861783
Drug: Chronic (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chronic (4 weeks) empagliflozin administration
Study: 22458741
Drug: Telmisartan/Amlodipine (T/A)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan/Amlodipine (T/A) single-pill combination (SPC)
Study: 17011678
Drug: Intradermal (ID)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal (ID) injection of 0.1 ml dose of inactivated split‐virion influenza vaccine
Study: 17011678
Drug: Intramuscular (IM)
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular (IM) injection of 0.5 ml dose of inactivated split‐virion influenza vaccine
Study: 15843666
Drug: Azithromycin 600
Normalized name: azithromycin 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 600 mg weekly for one year
Study: 7569455
Drug: 30 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 µg of estrogen and 300 µg of progestogen (Group 2)
Study: 7569455
Drug: 35 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 35 µg of estrogen and 500 µg of progestogen (Group 3)
Study: 7569455
Drug: 30 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 µg of levonorgestrel (Group 4)
Study: 2169779
Drug: Granisetron 40
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Granisetron 40 micrograms/kg (additional doses for breakthrough nausea)
Study: 6986949
Drug: Captopril, 100
Normalized name: Captopril, 100 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril, 100 mg orally
Study: 27735931
Drug: Inhaled hydrofluoalkane-beclomethasone
Normalized name: beclomethasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled hydrofluoalkane-beclomethasone dipropionate (QVAR) 100 μg per dose, twice daily via Aerochamber with face mask
Study: 23949258
Drug: EHK02‐01 cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: EHK02‐01 cream applied twice daily for 28 days
Study: 23949258
Drug: Control cream
Normalized name: BENZOYL PEROXIDE 3 mg in 60 mL TOPICAL LIQUID [Acnecare Dermacontrol Cream]
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control cream applied twice daily for 28 days
Study: 22575040
Drug: L-alanylglutamine (AlaGln)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-alanylglutamine (AlaGln) at 89 mg/kg
Study: 22575040
Drug: L-glutamine (L-Gln)
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-glutamine (L-Gln) at 60 mg/kg
Study: 22575040
Drug: Enzymatically hydrolyzed
Normalized name: hydrolyzed sericin (enzymatic; 2500 MW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzymatically hydrolyzed wheat protein (HWP) at 200 mg/kg
Study: 19412108
Drug: Remifentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil infusion (0.03‐0.1 microg kg min)
Study: 19412108
Drug: Fentanyl (1‐3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (1‐3 microg kg) and midazolam (0.05‐0.1 mg kg)
Study: 12355937
Drug: Concurrent chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiotherapy for localized disease of both small and non-small cell lung cancers
Study: 12355937
Drug: Adjuvant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant treatment methods for resected patients
Study: 17846310
Drug: G-CSF (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF (10 microg/kg/d)
Study: 1097925
Drug: Propranolol (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (160 to 320 mg per day for six and 12 weeks)
Study: 31326727
Drug: liraglutide/metformin
Approvals — FDA: no, EMA: no, PMDA: no
Description: liraglutide/metformin
Study: 23155151
Drug: boceprevir (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: boceprevir (800 mg, 3 times daily) for 6 days followed by atazanavir (300 mg once daily) with ritonavir (100 mg) on days 10-31, plus concomitant boceprevir on days 25-31
Study: 23155151
Drug: boceprevir (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: boceprevir (800 mg, 3 times daily) for 6 days followed by lopinavir (400 mg twice daily) with ritonavir (100 mg) on days 10-31, plus concomitant boceprevir on days 25-31
Study: 23155151
Drug: boceprevir (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: boceprevir (800 mg, 3 times daily) for 6 days followed by darunavir (600 mg twice daily) with ritonavir (100 mg) on days 10-31, plus concomitant boceprevir on days 25-31
Study: 23155151
Drug: boceprevir (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: boceprevir (800 mg, 3 times daily)
Study: 19672236
Drug: Acatinol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acatinol (10 mg daily)
Study: 19672236
Drug: Piracetam (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piracetam (1200 mg daily)
Study: 16968405
Drug: Anti-IL-12 monoclonal
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-IL-12 monoclonal antibody
Study: 16281467
Drug: Salk Polio
Normalized name: poliovirus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salk Polio Vaccine
Study: 8280654
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Tamoxifen and Megestrol acetate
Study: 2879457
Drug: Calcium entry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium entry blocker (nitrendipine)
Study: 2879457
Drug: Beta adrenoreceptor
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta adrenoreceptor blocker (oxprenolol)
Study: 31829907
Drug: Ganetespib 150
Normalized name: Ganetespib
DrugBank: Ganetespib (DB12047)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganetespib 150 mg/m2 on days 1 and 15 with docetaxel 75 mg/m2 on day 1 of a 21-day cycle
Study: 29936130
Drug: Noninvasive image-guided
Normalized name: triclosan
DrugBank: Triclosan (DB08604)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Noninvasive image-guided breast brachytherapy (NIBB) with a total dose of 28.5 Gy in five daily fractions.
Study: 23139021
Drug: Guided Internet-delivered
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided Internet-delivered cognitive behavioural therapy for 8 weeks
Study: 20477925
Drug: Acyclovir (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acyclovir (400 mg five times a day for 1 week)
Study: 18565240
Drug: Subcutaneous epoetin
Normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous epoetin beta (6000 IU weekly for 2 weeks)
Study: 18565240
Drug: Subcutaneous darbepoetin
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous darbepoetin alfa (30 mug weekly for 2 weeks)
Study: 16648085
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment based on acupuncture diagnosis
Study: 16648085
Drug: Standardized treatments
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized treatments
Study: 9176531
Drug: Intrapleural streptokinase,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrapleural streptokinase, 250,000 i.u. daily for three days
Study: 1545974
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution intra‐alveolar dressings
Study: 16353046
Drug: Enalapril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (10 mg) with hydrochlorothiazide (25 mg)
Study: 16353046
Drug: Captopril (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (50 mg) with hydrochlorothiazide (25 mg)
Study: 10924001
Drug: d,l‐fenfluramine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: d,l‐fenfluramine (100 mg orally)
Study: 1387512
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide (IB) 40 micrograms via metered dose inhaler (MDI)
Study: 1387512
Drug: Fenoterol (not
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoterol (not specified dosage)
Study: 6516414
Drug: Theophylline administered
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Theophylline administered in aqueous solution
Study: 6516414
Drug: Theophylline oral
Normalized name: theophylline Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline oral preparations
Study: 6516414
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of Theophylline
Study: 27137756
Drug: sufentanil 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: sufentanil 2.5 μg
Study: 27137756
Drug: sufentanil 5
Normalized name: SUFentanil 50 MCG in 1 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: sufentanil 5 μg
Study: 27137756
Drug: fentanyl 25
Normalized name: FENTANYL 25MCG/HR PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: fentanyl 25 μg
Study: 24835719
Drug: Formulary applications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulary applications for new drugs or new indications (95 applications)
Study: 24835719
Drug: Applications reviewed
Normalized name: Renewal
DrugBank: Triclosan (DB08604)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Applications reviewed by statewide medicines advisory committee or hospital pharmacist (45 applications)
Study: 18049317
Drug: ADHD medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADHD medication use
Study: 11834115
Drug: Creatine (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine (0.3 g x kg(‐1) x d(‐1)) with 1-minute recovery interval
Study: 11834115
Drug: Creatine (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine (0.3 g x kg(‐1) x d(‐1)) with 3-minute recovery interval
Study: 7743615
Drug: Thrombolytic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic therapy with intravenous recombinant tissue-type plasminogen activator (rTPA)
Study: 30605708
Drug: Add-on 10Hz
Approvals — FDA: no, EMA: no, PMDA: no
Description: Add-on 10Hz rTMS treatment (20 times)
Study: 23759326
Drug: Screening every
Normalized name: SUN PROTECTANTS/SCREENS,TOPICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Screening every 4 years with PSA level cut-off ≥ 3.0 ng/ml as biopsy indication (S-arm)
Study: 21342773
Drug: Adenosine pretreatment
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adenosine pretreatment (2.45 mg kg⁻¹ over 10 min)
Study: 18539916
Drug: Intensive glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive glucose control (gliclazide modified release plus other drugs)
Study: 12768462
Drug: Acamprosate (1332
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acamprosate (1332 mg daily)
Study: 8898507
Drug: Transdermal fentanyl
Normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Transdermal fentanyl 25 micrograms/hr
Study: 8898507
Drug: Transdermal fentanyl
Normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Transdermal fentanyl 50 micrograms/hr
Study: 1725280
Drug: PPF (DDP
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPF (DDP 100 mg/m2 + pingyangmycin + 5‐FU) regimen plus radiotherapy
Study: 27854209
Drug: Aceneuramic acid
Normalized name: ACENEURAMIC ACID
DrugBank: Aceneuramic acid (DB11797)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aceneuramic acid extended-release (Ace-ER) 6g/day
Study: 27854209
Drug: Aceneuramic acid
Normalized name: ACENEURAMIC ACID
DrugBank: Aceneuramic acid (DB11797)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aceneuramic acid extended-release (Ace-ER)
Study: 24559216
Drug: Intensive combination
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive combination treatment strategies (ICTS) for early RA
Study: 24559216
Drug: Conventional disease-modifying
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional disease-modifying anti-rheumatic drugs (DMARDs) plus step-down glucocorticoids (GCs)